{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:26:43Z","timestamp":1777858003826,"version":"3.51.4"},"reference-count":51,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T00:00:00Z","timestamp":1219276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p>\n                    Asenapine, a novel psychopharmacologic agent being developed for the treatment of schizophrenia and bipolar disorder, has high affinity for a wide range of receptors, including the serotonergic receptors 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    , 5-HT\n                    <jats:sub>1B<\/jats:sub>\n                    , 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    , 5-HT\n                    <jats:sub>2B<\/jats:sub>\n                    , 5-HT\n                    <jats:sub>2C<\/jats:sub>\n                    , 5-HT\n                    <jats:sub>5A<\/jats:sub>\n                    , 5-HT\n                    <jats:sub>6<\/jats:sub>\n                    and 5-HT\n                    <jats:sub>7<\/jats:sub>\n                    . We examined the long-term effects in rat brain of multiple doses of asenapine on representative serotonin receptor subtypes: 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    , 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    and 5-HT\n                    <jats:sub>2C<\/jats:sub>\n                    . Rats were given asenapine (0.03, 0.1 or 0.3 mg\/kg) subcutaneously twice daily or vehicle for 4 weeks. Brain sections were collected from the medial prefrontal cortex (mPFC), dorsolateral frontal cortex (DFC), caudate putamen, nucleus accumbens, hippocampal CA\n                    <jats:sub>1<\/jats:sub>\n                    and CA\n                    <jats:sub>3<\/jats:sub>\n                    regions, and entorhinal cortex and processed for in-vitro receptor autoradiography. Asenapine 0.1 and 0.3 mg\/kg significantly increased 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    binding in mPFC (by 24% and 33%, respectively), DFC (27%, 31%) and hippocampal CA\n                    <jats:sub>1<\/jats:sub>\n                    region (23%, 25%) (all P &lt; 0.05). All three asenapine doses (0.03, 0.1 and 0.3 mg\/kg) significantly decreased 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    binding by a similar degree in mPFC (40%, 44%, 47%, respectively) and DFC (45%, 51%, 52%) (all P &lt; 0.05), but did not alter 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    binding in the other brain regions studied. In contrast to the effects on 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    and 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    receptors, asenapine did not alter 5-HT\n                    <jats:sub>2C<\/jats:sub>\n                    binding in any brain region examined at the doses tested. Our results indicate that repeated administration of asenapine produces regional-specific effects on 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    and 5-HT\n                    <jats:sub>2A<\/jats:sub>\n                    receptors in rat forebrain regions, which may contribute to the distinctive psychopharmacologic profile of asenapine.\n                  <\/jats:p>","DOI":"10.1177\/0269881108095704","type":"journal-article","created":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T21:09:51Z","timestamp":1219352991000},"page":"341-348","source":"Crossref","is-referenced-by-count":31,"title":["Asenapine induces differential regional effects on serotonin receptor subtypes"],"prefix":"10.1177","volume":"24","author":[{"given":"FI","family":"Tarazi","sequence":"first","affiliation":[{"name":"Mailman Research Center, McLean Division of Massachusetts General Hospital, Belmont, MA, USA, , Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Moran-Gates","sequence":"additional","affiliation":[{"name":"Mailman Research Center, McLean Division of Massachusetts General Hospital, Belmont, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EHF","family":"Wong","sequence":"additional","affiliation":[{"name":"Pfizer Global R&D, Ann Arbor, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Henry","sequence":"additional","affiliation":[{"name":"Schering-Plough Corporation, Newhouse, Lanarkshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Shahid","sequence":"additional","affiliation":[{"name":"Schering-Plough Corporation, Newhouse, Lanarkshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,8,21]]},"reference":[{"key":"atypb1","unstructured":"Baldessarini, RJ, Tarazi, FI ( 2005) Pharmacotherapy of psychosis and mania. In: Brunton, LL, Lazo, JS , Parker, KL (eds.), Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics . New York, NY: McGraw-Hill , pp. 461-500."},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00225-1"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/14.2.297"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(96)00062-0"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1358\/dof.1993.018.12.230456"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2999-05.2005"},{"key":"atypb7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-3565(24)36475-4","volume":"280","author":"Florijn, WJ","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-007-0973-y"},{"key":"atypb9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0022-3565(25)11149-X","volume":"261","author":"Francis, PT","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.56.070187.003151"},{"key":"atypb11","unstructured":"Greene, WH ( 2000) Econometric Analysis, fourth ed. Upper Saddle River, NJ: Prentice Hall, pp 462-465."},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00321-1"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245005"},{"key":"atypb14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","volume":"46","author":"Hoyer, D.","year":"1994","journal-title":"Pharmacol Rev"},{"key":"atypb15","author":"Huang, M.","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00154.x"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.58.060904.084114"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1038\/npp.1993.32"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurx.2005.12.003"},{"key":"atypb20","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0022-3565(25)10140-7","volume":"264","author":"Kuoppamaki, M.","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1993.01820220066007"},{"key":"atypb22","first-page":"214","volume":"3","author":"Leysen, JE","year":"1987","journal-title":"Psychopharmacol Ser"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(99)00046-9"},{"key":"atypb24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0031-6997(25)06671-2","volume":"43","author":"Meltzer, HY","year":"1991","journal-title":"Pharmacol Rev"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2003.09.010"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(90)90330-7"},{"key":"atypb27","first-page":"853","volume":"295","author":"Millan, MJ","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(86)90332-X"},{"key":"atypb29","first-page":"105","volume":"81","author":"Neill, JC","year":"2006","journal-title":"Schizophr Res"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.12.003"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890060205"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245003"},{"key":"atypb33","first-page":"205","volume":"346","author":"Pazos, A.","year":"1985","journal-title":"I. Serotonin-1 receptors. Brain Res"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.12-02-00440.1992"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1004"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00859-6"},{"key":"atypb37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)29304-6","volume":"299","author":"Rauser, L.","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb38","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0022-3565(25)11452-3","volume":"260","author":"Roth, BL","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb39","first-page":"17","volume":"174","author":"Roth, BL","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"atypb40","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245606"},{"key":"atypb41","author":"Shahid, M.","year":"2008","journal-title":"J Psychopharmacol"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(95)00026-7"},{"key":"atypb43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4000920"},{"key":"atypb44","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)01361-X"},{"key":"atypb45","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0022-3565(24)29589-6","volume":"297","author":"Tarazi, FI","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb46","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1016-3"},{"key":"atypb47","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216010-00003"},{"key":"atypb48","doi-asserted-by":"publisher","DOI":"10.1038\/374542a0"},{"key":"atypb49","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09516-1","volume":"38","author":"Teitler, M.","year":"1990","journal-title":"Mol Pharmacol"},{"key":"atypb50","unstructured":"Winer, BJ, Brown, DR, Michels, KM ( 1991) Statistical Principles in Experimental Design, third ed . New York: McGraw Hill , pp. 165-166."},{"key":"atypb51","doi-asserted-by":"publisher","DOI":"10.1002\/cne.903510304"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108095704","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108095704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:05:44Z","timestamp":1777507544000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881108095704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,21]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1177\/0269881108095704"],"URL":"https:\/\/doi.org\/10.1177\/0269881108095704","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,21]]}}}